Common diabetic therapy
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Breast Cancer ~ Swine Flu ~ Lung Cancer ~ Heart attack ~ Pregnancy ~ All Health Topics
Home / Health News / 2009 / August 2009 / August 2, 2009
Common diabetic therapy reduces pancreatic cancer risk
RSS / Print / Comments

Diabetes

Metabolic status prior to pregnancy predicts subsequent gestational diabetes

New gene could explain relationship between diabetes, Alzheimer's

Scientists reveal new clues to origin of diabetes

More on Diabetes

Health News

Blame your mom for your muffin top or thunder thighs
A new study by an international team of researchers, including Cambridge and Oxford experts, has revealed that our propensity to be apple or pear-shaped is at least partly in our genes. ANI

Blame your mom for your muffin top or thunder thighs
A new study by an international team of researchers, including Cambridge and Oxford experts, has revealed that our propensity to be apple or pear-shaped is at least partly in our genes. ANI

Meta-analysis shows folic acid supplements not beneficial for heart
A new meta-analysis has shown that the use of folic acid supplements does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period. ANI

Common diabetic therapy reduces pancreatic cancer risk

A commonly prescribed anti-diabetic drug can reduce an individuals risk of developing pancreatic cancer by 62 percent, according to a new study.


Washington, Aug 2 : A commonly prescribed anti-diabetic drug can reduce an individual's risk of developing pancreatic cancer by 62 percent, according to a new study.

The research from The University of Texas M. D. Anderson Cancer Center has been published in the Aug. 1 issue of Gastroenterology.

"This is the first epidemiological study of metformin in the cancer population, and it offers an exciting direction for future chemoprevention research for a disease greatly in need of both treatment and prevention strategies," said Donghui Li, Ph.D., professor in M. D. Anderson's Department of Gastrointestinal Medical Oncology.

"Metformin works by increasing the cellular sensitivity to insulin and decreasing its level circulating in diabetics. Insulin also seems to have a growth-promoting effect in cancer," said Li, the study's senior author.

"Metformin activates the AMP kinase, which is a cellular engery sensor. Recent publications have described that AMP kinase also plays an important role in the development of cancer by controlling cell division and growth," the expert added.

Li also cited a previous animal study showing that metformin prevented pancreatic tumor development, as well as numerous epidemiologic studies in the diabetic population that showed taking the drug reduced the risk for cancer overall.

"Given these earlier findings, and knowing that diabetes is a risk factor for the development of pancreatic cancer and that 10 percent of such cancers are associated with diabetes, we wanted to better understand the specific association between different anti-diabetic therapies and this lethal disease," explained Li.

For the case control study, the researchers enrolled 1,838 participants - 973 patients with pancreatic adenocarcinoma treated at M. D. Anderson between 2004 and 2008 to compare 863 cancer-free individuals, all companions of M. D. Anderson patients.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us